These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. US geographic distribution of rt-PA utilization by hospital for acute ischemic stroke. Kleindorfer D; Xu Y; Moomaw CJ; Khatri P; Adeoye O; Hornung R Stroke; 2009 Nov; 40(11):3580-4. PubMed ID: 19797701 [TBL] [Abstract][Full Text] [Related]
3. Do billing codes accurately capture intravenous tissue plasminogen activator treatment rates? Justified concern for clinical performance measures based on billing code assignment. Palazzo P; Alexandrov AV; Alexandrov AW J Stroke Cerebrovasc Dis; 2015 Feb; 24(2):327-9. PubMed ID: 25498735 [TBL] [Abstract][Full Text] [Related]
4. Utilization of intravenous thrombolysis in 3-4.5 hours: analysis of the Minnesota stroke registry. Tekle WG; Chaudhry SA; Hassan AE; Peacock JM; Lakshminarayan K; Tsai A; Luepker R; Anderson DC; Qureshi AI Cerebrovasc Dis; 2012; 34(5-6):400-5. PubMed ID: 23221276 [TBL] [Abstract][Full Text] [Related]
5. Tissue plasminogen activator (rt-PA) in acute ischemic stroke: Outcomes associated with ambulation. Lawson TR; Brown IE; Westerkam DL; Blackhurst DW; Sternberg S; Leacock R; Nathaniel TI Restor Neurol Neurosci; 2015; 33(3):301-8. PubMed ID: 25698111 [TBL] [Abstract][Full Text] [Related]
6. Recombinant tissue-type plasminogen activator use for ischemic stroke in the United States: a doubling of treatment rates over the course of 5 years. Adeoye O; Hornung R; Khatri P; Kleindorfer D Stroke; 2011 Jul; 42(7):1952-5. PubMed ID: 21636813 [TBL] [Abstract][Full Text] [Related]
7. Recombinant tissue plasminogen activator (rt-PA) utilisation by rural clinicians in acute ischaemic stroke: an audit of current practice and clinical outcomes. Williams JM; Navin TJ; Jude MR; Levi CR Aust J Rural Health; 2013 Aug; 21(4):203-7. PubMed ID: 24033520 [TBL] [Abstract][Full Text] [Related]
8. Factors associated with the administration of tissue plasminogen activator for acute ischemic stroke. Kunisawa S; Kobayashi D; Lee J; Otsubo T; Ikai H; Yokota C; Minematsu K; Imanaka Y J Stroke Cerebrovasc Dis; 2014 Apr; 23(4):724-31. PubMed ID: 23910512 [TBL] [Abstract][Full Text] [Related]
9. Accuracy of the new ICD-9-CM code for "drip-and-ship" thrombolytic treatment in patients with ischemic stroke. Tonarelli SB; Tibbs M; Vazquez G; Lakshminarayan K; Rodriguez GJ; Qureshi AI J Stroke Cerebrovasc Dis; 2012 Feb; 21(2):121-3. PubMed ID: 20851622 [TBL] [Abstract][Full Text] [Related]
10. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China. Yan X; Hu HT; Liu S; Sun YH; Gao X Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471 [TBL] [Abstract][Full Text] [Related]
12. Use and in-hospital outcomes of recombinant tissue plasminogen activator in pediatric arterial ischemic stroke patients. Nasr DM; Biller J; Rabinstein AA Pediatr Neurol; 2014 Nov; 51(5):624-31. PubMed ID: 25194722 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs. Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Wardlaw J Stroke; 2004 Jun; 35(6):1490-7. PubMed ID: 15105519 [TBL] [Abstract][Full Text] [Related]
14. The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke. Kahn JH; Viereck J; Kase C; Jeerakathil T; Romero R; Mehta SD; Kociol R; Babikian V J Emerg Med; 2005 Oct; 29(3):273-7. PubMed ID: 16183445 [TBL] [Abstract][Full Text] [Related]
15. Long-term outcome as function of blood pressure in acute ischemic stroke and effects of thrombolysis. Yong M; Diener HC; Kaste M; Mau J Cerebrovasc Dis; 2007; 24(4):349-54. PubMed ID: 17690547 [TBL] [Abstract][Full Text] [Related]
16. Pennsylvania comprehensive stroke center collaborative: Statement on the recently updated IV rt-PA prescriber information for acute ischemic stroke. Daou B; Deprince M; D'Ambrosio R; Tjoumakaris S; Rosenwasser RH; Ackerman DJ; Bell R; Tzeng DL; Ghobrial M; Fernandez A; Shah Q; Gzesh DJ; Murphy D; Castaldo JE; Mathiesen C; Pineda MC; Jabbour P Clin Neurol Neurosurg; 2015 Dec; 139():264-8. PubMed ID: 26539671 [TBL] [Abstract][Full Text] [Related]
17. A pilot study of dual treatment with recombinant tissue plasminogen activator and uric acid in acute ischemic stroke. Amaro S; Soy D; Obach V; Cervera A; Planas AM; Chamorro A Stroke; 2007 Jul; 38(7):2173-5. PubMed ID: 17525395 [TBL] [Abstract][Full Text] [Related]
18. Intravenous thrombolysis for acute ischemic stroke in the 3- to 4·5-hour window--the Malabar experience. Salam KA; Ummer K; Pradeep Kumar VG; Noone ML Int J Stroke; 2014 Jun; 9(4):426-8. PubMed ID: 23981667 [TBL] [Abstract][Full Text] [Related]
19. Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke? Hassan AE; Chaudhry SA; Jani V; Grigoryan M; Khan AA; Adil MM; Qureshi AI J Stroke Cerebrovasc Dis; 2013 May; 22(4):545-9. PubMed ID: 23453555 [TBL] [Abstract][Full Text] [Related]
20. Sex differences in the use of intravenous rt-PA thrombolysis treatment for acute ischemic stroke: a meta-analysis. Reeves M; Bhatt A; Jajou P; Brown M; Lisabeth L Stroke; 2009 May; 40(5):1743-9. PubMed ID: 19228855 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]